Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3651 - Health-related quality of life (HRQL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (CBZ) in a prospective observational study (CAPRISTANA)

Date

10 Sep 2017

Session

Poster display session

Presenters

Angelika Pichler

Citation

Annals of Oncology (2017) 28 (suppl_5): v269-v294. 10.1093/annonc/mdx370

Authors

A. Pichler1, G. Barnes2, J. Katolicka3, H. Korunkova4, A. Tomova5, M. Ghosn6, F. El Karak6, I. Koroleva7, J. Makdessi8, A. Ozatilgan9, S. Hitier10, J. Carles11

Author affiliations

  • 1 Department Of Hematology And Oncology, Landeskrankenhaus LKH Leoben, 8700 - Leoben/AT
  • 2 Department Of Biostatistics, Sanofi, Cambridge/US
  • 3 Department Of Oncology, St. Ann's University Hospital, Brno/CZ
  • 4 Department Of Oncology And Radiotherapy, University Hospital, Plzen/CZ
  • 5 Department Of Oncology, Complex Oncology Center, 4004 - Plovdiv/BG
  • 6 Department Of Hematology And Oncology, Hotel Dieu de France Hospital, 1107 2020 - Beirut/LB
  • 7 Department Of Medicine, Medical University “Reaviz", Samara/RU
  • 8 Department Of Medicine, St. George Hospital, 001 - Beirut/LB
  • 9 Global Medical Affairs Oncology, Sanofi, Boston/US
  • 10 Department Of Biostatistics, Sanofi, 91385 - Chilly-Mazarin/FR
  • 11 Vall D’hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona/ES
More

Resources

Abstract 3651

Background

Cabazitaxel (CBZ) is a taxane approved for mCRPC treatment post docetaxel based on Phase 3 clinical trial data. Observational studies are in progress to gather information on real-world treatment patterns, safety, efficacy and HRQL effect of CBZ outside of clinical trials.

Methods

The prospective, observational study CAPRISTANA evaluated the routine clinical use of CBZ (25 mg/m2 every 3 weeks plus prednisone 10 mg/day) in pts with mCRPC previously treated with docetaxel. HRQL was assessed using Functional Assessment of Cancer Therapy - Prostate (FACT-P) version 4 and EQ-5D-3L (including VAS - visual analogue scale) questionnaires at baseline and every two cycles until CBZ discontinuation.

Results

A total of 192 pts were treated in 55 centers across 6 countries (Apr 2012–Jun 2016); 161 and 157 pts were evaluable for FACT-P and EQ-5D, respectively. Pts received 6 (median) cycles of CBZ (range 1–24); 53.6% achieved disease control with CBZ. The main reason for CBZ treatment discontinuation was disease progression (58.3%). No new safety signals were identified. In the overall FACT-P score analysis, HRQL improvement during CBZ treatment was recorded in 31.8%, no change in HRQL in 40.4%, and deterioration was recorded in 27.8% of pts. The highest rate of improvement was observed for the Prostate-Specific Concerns subscale (49.3%) and Pain Control subscale (54.2%). The highest rate of deterioration was recorded for the Functional Well-Being subscale (40.9%). Mean FACT-P score and EQ-5D health utility index and VAS scores did not show statistically significant changes during CBZ treatment.

Conclusions

In this real-world study investigating HRQL associated with the use of CBZ in pts with mCRPC, no significant changes were observed in mean on-treatment FACT-P score and EQ-5D scores. However, in contrast to observations in prospective clinical studies, pts had improvement in the Pain Control FACT-P subscale. These results suggest that, in addition to the previously demonstrated effectiveness, CBZ treatment may help pts to achieve better pain control.

Clinical trial identification

Legal entity responsible for the study

Sanofi

Funding

Sanofi

Disclosure

G. Barnes: Employee of Sanofi. M. Ghosn: Advisory boards for Sanofi, Astellas and Janssen. I. Koroleva: Research funding and speakers' bureau for AstraZeneca and Teva, travel reimbursement from MSD and Eisai. A. Ozatilgan: Employee of Sanofi. S. Hitier: Employee of Sanofi. J. Carles: Consulting/advisory role to Johnson&Johnson, Bayer, Astellas, BMS, Pfizer and Sanofi. All other authors have declared no conflicts of interest.

Disclosure

G. Barnes: Employee of Sanofi. M. Ghosn: Advisory boards for Sanofi, Astellas and Janssen. I. Koroleva: Research funding and speakers\' bureau for AstraZeneca and Teva, travel reimbursement from MSD and Eisai. A. Ozatilgan: Employee of Sanofi. S. Hitier: Employee of Sanofi. J. Carles: Consulting/advisory role to Johnson&Johnson, Bayer, Astellas, BMS, Pfizer and Sanofi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.